Revolution Medicines Doses First Patient in Phase I/Ib Clinical Trial of RMC-9805, an Oral, Covalent, Mutant-Selective KRASG12D(ON) Inhibitor

Revolution Medicines, Inc. announced the first patient was dosed in its Phase I/Ib monotherapy clinical trial of RMC-9805, an oral, covalent, mutant-selective KRASG12D(ON) Inhibitor designed to treat patients with cancers driven by the KRASG12D mutation.